Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

BackgroundUnderstanding the effect of immunity on P. falciparum clearance is essential for interpreting therapeutic efficacy studies designed to monitor emergence of artemisinin drug resistance. In low transmission areas of Southeast Asia, where resistance has emerged, P. falciparum antibodies confound parasite clearance measures. However, variation in naturally acquired antibodies across Asian and sub-Saharan African epidemiological contexts and their impact on parasite clearance, is yet to be quantified.MethodsIn an artemisinin therapeutic efficacy study, antibodies to twelve pre-erythrocytic and erythrocytic P. falciparum antigens were measured in 118 children with uncomplicated P. falciparum malaria in Democratic Republic of Congo (DRC) and compared to responses in patients from Asian sites, described previously.ResultsParasite clearance half-life was faster in DRC patients (median 2 hours) compared to most Asian sites (median ranged from 2-7 hours), but P. falciparum antibody levels and seroprevalences were similar. There was no evidence for an association between antibody seropositivity and parasite clearance half-life (mean difference between seronegative and seropositive ranged from -0.14 and +0.40 h) in DRC patients.ConclusionsIn DRC, where artemisinin remains highly effective, the substantially faster parasite clearance time compared with Asia was not explained by differences in the P. falciparum antibody responses studied.

Original publication

DOI

10.1093/infdis/jiac232

Type

Journal article

Journal

The Journal of infectious diseases

Publication Date

15/06/2022

Addresses

Burnet Institute, Melbourne, Victoria 3004, Australia.